Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cyclophosphamide + Fludarabine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
| Fludarabine | Fludara | FAMP|Fludarabine phosphate | Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07055477 | Phase I | Anti-CCR4 CAR-T cells Cyclophosphamide + Fludarabine | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) | Recruiting | USA | 0 |
| NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Active, not recruiting | CAN | 0 |
| NCT05678205 | Phase Ib/II | AB-201 Cyclophosphamide + Fludarabine | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | Withdrawn | USA | 1 |
| NCT02995330 | Phase I | Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Tacrolimus + Testosterone cypionate Cyclophosphamide + Fludarabine | Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer | Terminated | USA | 0 |
| NCT05618925 | Phase I | Cyclophosphamide + Fludarabine CD19 t-haNK cells + Rituximab CD19 t-haNK cells + Nogapendekin alfa inbakicept + Rituximab | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | Recruiting | USA | 0 |
| NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T-cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |
| NCT03019666 | Phase I | Allogeneic NAM NK cells Cyclophosphamide + Fludarabine | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | Completed | USA | 0 |
| NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
| NCT03635632 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Active, not recruiting | USA | 0 |
| NCT06777979 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
| NCT07072234 | Phase I | Cyclophosphamide + Fludarabine TGFBR2 KO Anti-CD70 CAR-NK cells Dexamethasone | Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |
| NCT06326463 | Phase I | CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | Recruiting | USA | 0 |
| NCT06961357 | Phase Ib/II | Interleukin-12 CD40L-augmented TILs Cyclophosphamide + Fludarabine | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Recruiting | USA | 0 |
| NCT04245839 | Phase II | Lisocabtagene maraleucel Cyclophosphamide + Fludarabine | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) | Active, not recruiting | USA | SWE | ITA | GBR | FRA | ESP | DEU | CAN | AUT | 1 |
| NCT03873805 | Phase I | Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR-T cells | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT05114837 | Phase Ib/II | CAR19-tTreg Cyclophosphamide + Fludarabine | Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL | Withdrawn | USA | 0 |
| NCT06236425 | Phase I | Cisplatin + Pembrolizumab Aldesleukin Carboplatin + Fluorouracil + Pembrolizumab TBio-4101 Cyclophosphamide + Fludarabine Cisplatin + Fluorouracil + Pembrolizumab | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | Active, not recruiting | USA | 0 |
| NCT04608487 | Phase I | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Axi-cel in CNS Lymphoma | Active, not recruiting | USA | 0 |
| NCT02830724 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + Anti-hCD70 CAR-T cells | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | Recruiting | USA | 0 |
| NCT07015242 | Phase II | Lisocabtagene maraleucel Temozolomide Methotrexate Rituximab Cyclophosphamide + Fludarabine Procarbazine | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Recruiting | USA | FRA | DEU | 0 |
| NCT06834282 | Phase I | CER-1236 Cyclophosphamide + Fludarabine | CER-1236 in Patients With Acute Myeloid Leukemia (AML) (CertainT-1) | Recruiting | USA | 0 |
| NCT05694364 | Phase I | PRGN-3007 Cyclophosphamide Cyclophosphamide + Fludarabine | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | Active, not recruiting | USA | 0 |
| NCT05826535 | Phase Ib/II | Cyclophosphamide + Fludarabine IMPT-314 | Study of LYL314 in Aggressive Large B-Cell Lymphoma | Recruiting | USA | 0 |
| NCT03139370 | Phase I | Cyclophosphamide + Fludarabine KITE-718 | Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | Terminated | USA | 0 |
| NCT01701674 | Phase I | Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | Completed | USA | 0 |
| NCT04323657 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-110 T-cells | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Completed | USA | 0 |
| NCT04848064 | Phase I | Cyclophosphamide + Fludarabine Mogamulizumab | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | Recruiting | USA | 0 |
| NCT06968195 | Phase I | RPCAR01 Cyclophosphamide + Fludarabine | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma | Suspended | USA | 0 |
| NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
| NCT06305299 | Phase I | Cyclophosphamide + Fludarabine iC9-CAR.B7-H3 T-cells | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | Recruiting | USA | 0 |
| NCT06748872 | Phase I | MDG1015 Cyclophosphamide + Fludarabine | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma (EPITOME-1015-I) | Not yet recruiting | USA | 0 |
| NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Suspended | USA | 0 |
| NCT04394650 | Phase I | Cyclophosphamide + Fludarabine CC-98633 | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma | Completed | USA | 0 |
| NCT07166419 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
| NCT04103879 | Phase II | ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil | US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | Active, not recruiting | USA | NLD | 0 |
| NCT05451849 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-510 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | 0 |
| NCT05633615 | Phase II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT05495464 | Phase I | Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
| NCT05639972 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + E7 TCR T-cells | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | Recruiting | USA | 0 |
| NCT06698744 | Phase I | Cyclophosphamide + Fludarabine UF-KURE-BCMA CAR-T cells | UF-KURE-BCMA CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma | Not yet recruiting | USA | 0 |
| NCT03215810 | Phase I | Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
| NCT04892277 | Phase I | Bendamustine IC19/1563 Cyclophosphamide + Fludarabine | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | Recruiting | USA | 0 |
| NCT04310592 | Phase I | Cyclophosphamide + Fludarabine CYNK-001 | Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01) | Terminated | USA | 0 |
| NCT02774291 | Phase I | Aldesleukin Cyclophosphamide + Fludarabine Filgrastim | Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 | Terminated | USA | 0 |
| NCT05077527 | Phase I | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
| NCT05182073 | Phase I | Cyclophosphamide + Fludarabine FT576 Daratumumab + FT576 | FT576 in Subjects With Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT06026319 | Phase I | CD79b-19 CAR T cells Cyclophosphamide + Fludarabine | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
| NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
| NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT06079164 | Phase I | KITE-197 Cyclophosphamide + Fludarabine | Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma | Active, not recruiting | USA | CAN | AUS | 0 |
| NCT04714372 | Phase I | Cyclophosphamide + Fludarabine Daratumumab and hyaluronidase-fihj + FT538 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | Completed | USA | 0 |
| NCT00167180 | Phase II | Cyclophosphamide + Fludarabine | Post Transplant Donor Lymphocyte Infusion | Terminated | USA | 0 |
| NCT05665062 | Phase I | Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
| NCT05748197 | Phase I | Cyclophosphamide + Fludarabine ADCLEC.syn1 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Recruiting | USA | 0 |
| NCT05922930 | Phase Ib/II | TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | Recruiting | USA | 0 |
| NCT06096038 | Phase Ib/II | iC9.CAR-CSPG4 T-cells Cyclophosphamide + Fludarabine | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Recruiting | USA | 0 |
| NCT00338377 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin | Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
| NCT03971799 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD33 CAR-T cells | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Completed | USA | 0 |
| NCT07162038 | Phase I | Cyclophosphamide + Fludarabine Allogeneic CD19-CD28-CD3-zeta CAR-T cells + Mycophenolate mofetil + Sirolimus | Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation | Recruiting | USA | 0 |
| NCT05703854 | Phase Ib/II | CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | Recruiting | USA | 0 |
| NCT05886491 | Phase Ib/II | Cyclophosphamide + Fludarabine GDX012 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT05478837 | Phase I | Cyclophosphamide + Fludarabine KIND T cells | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (PNOC018) | Recruiting | USA | 0 |
| NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
| NCT04670068 | Phase I | CAR.B7-H3T cells Cyclophosphamide + Fludarabine | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | Active, not recruiting | USA | 0 |
| NCT05418088 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
| NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
| NCT05963217 | Phase I | Cyclophosphamide + Fludarabine TBI-2001 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | Recruiting | CAN | 0 |
| NCT05310591 | Phase Ib/II | Cyclophosphamide + Fludarabine Nivolumab Tisagenlecleucel | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL) | Recruiting | FRA | 0 |
| NCT06486051 | Phase II | Cyclophosphamide + Fludarabine WZTL-002 | A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) | Recruiting | NZL | 0 |
| NCT06481592 | Phase II | Aldesleukin + Lifileucel Cyclophosphamide + Fludarabine | A Study of Lifileucel (tumor-infiltrating Lymphocytes) in Adults with Advanced Endometrial Cancer. | Recruiting | USA | 0 |
| NCT03912831 | Phase I | Cyclophosphamide + Fludarabine KITE-439 | Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers | Terminated | USA | 0 |
| NCT05334329 | Phase I | Cyclophosphamide + Fludarabine Atezolizumab TRACK-NK cells | Genetically Engineered Cells (COH06) With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | Active, not recruiting | USA | 0 |
| NCT06940297 | Phase II | Cyclophosphamide + Fludarabine Ciltacabtagene autoleucel Dasatinib + Quercetin | Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
| NCT06347068 | Phase I | iC9-CAR.B7-H3 T-cells Cyclophosphamide + Fludarabine | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | Recruiting | USA | 0 |
| NCT02905188 | Phase I | Anti-GPC3-scFvGC33-CAR autologous T lymphocytes Cyclophosphamide + Fludarabine | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | Completed | USA | 0 |
| NCT03448393 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Completed | USA | 0 |
| NCT07149857 | Phase II | Daratumumab + Dexamethasone + Lenalidomide Ciltacabtagene autoleucel Cyclophosphamide Bortezomib + Dexamethasone + Lenalidomide Cyclophosphamide + Fludarabine Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel (CARTITUDE-10) | Recruiting | USA | ESP | AUS | 0 |
| NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
| NCT06185751 | Phase I | Cyclophosphamide + Fludarabine WS-CART-CS1 | Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma | Recruiting | USA | 0 |
| NCT05949125 | Phase I | Cyclophosphamide + Fludarabine AVC-201 | Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | Recruiting | NLD | DEU | 0 |
| NCT06690281 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin + Autologous KRAS mutant TCR-transduced PBLs | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | Withdrawn | USA | 0 |
| NCT05625594 | Phase I | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Cyclophosphamide + Fludarabine | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma | Recruiting | USA | 0 |
| NCT06193486 | Phase I | MSGV1-PSCA-8T28Z Cyclophosphamide + Fludarabine | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | Recruiting | USA | 0 |
| NCT04314843 | Phase Ib/II | axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) | Terminated | USA | 0 |
| NCT06912529 | Phase II | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (PRIME-CAR) | Terminated | DEU | 0 |
| NCT06190249 | Phase I | Cyclophosphamide + Fludarabine Lifileucel Pembrolizumab Aldesleukin Mesna | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | Withdrawn | 0 | |
| NCT06043713 | Phase I | Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Suspended | USA | 0 |
| NCT03287817 | Phase Ib/II | Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) | Terminated | USA | GBR | 0 |
| NCT01256398 | Phase II | Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Completed | USA | 0 |
| NCT06236139 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-STEAP1 CAR-T cells + Enzalutamide | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT04196413 | Phase I | Cyclophosphamide + Fludarabine GD2 CAR T cells | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) | Recruiting | USA | 0 |
| NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Active, not recruiting | USA | 0 |
| NCT06615479 | Phase III | Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide BMS-986393 + Carfilzomib + Daratumumab + Dexamethasone + Pomalidomide Cyclophosphamide + Fludarabine | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
| NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
| NCT03166397 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab tumor infiltrating lymphocytes Ipilimumab | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | Recruiting | ISR | 0 |
| NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Active, not recruiting | USA | 0 |
| NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT07101432 | Phase I | TROP2 CAR/IL-15 TGFBR2 KO NK cells Cyclophosphamide + Fludarabine | Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK) | Active, not recruiting | USA | 0 |
| NCT07011004 | Phase I | Atezolizumab + CIML-NK cells Cyclophosphamide + Fludarabine | A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia | Recruiting | USA | 0 |
| NCT06153251 | Phase I | BMS-986453 Cyclophosphamide + Fludarabine | A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | DEU | 0 |
| NCT05371093 | Phase III | axicabtagene ciloleucel Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Fludarabine Bendamustine + Rituximab Lenalidomide + Rituximab | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 1 |
| NCT04167696 | Phase I | CYAD-02 Cyclophosphamide + Fludarabine | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) | Recruiting | USA | BEL | 0 |
| NCT06119685 | Phase Ib/II | IDP-023 Cyclophosphamide + Fludarabine Daratumumab + IDP-023 Aldesleukin + IDP-023 IDP-023 + Rituximab | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Recruiting | USA | 0 |
| NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Terminated | USA | 0 |
| NCT04809766 | Phase I | Bendamustine FH-TCR-TMSLN Cyclophosphamide + Fludarabine | Mesothelin-Specific T-Cells (FH-TCR-TMSLN) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
| NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Active, not recruiting | USA | 0 |
| NCT05628883 | Phase I | Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | Active, not recruiting | USA | 0 |
| NCT06237881 | Phase Ib/II | Cyclophosphamide + Fludarabine KSQ-001EX Aldesleukin + KSQ-001EX | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
| NCT05347485 | Phase II | Ciltacabtagene autoleucel Cyclophosphamide + Fludarabine | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | Completed | USA | 0 |
| NCT06847269 | Phase II | Mesna Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells | CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia | Recruiting | USA | 0 |
| NCT07225439 | Phase I | Aldesleukin + Rituximab + Tafasitamab-cxix Cyclophosphamide + Fludarabine | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Not yet recruiting | USA | 0 |
| NCT05714345 | Phase II | Cyclophosphamide + Fludarabine ALLO-647 + Cyclophosphamide + Fludarabine ALLO-501A | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND) | Active, not recruiting | USA | BEL | 0 |
| NCT06660420 | Phase I | PRAME-TCR-NK cells Cyclophosphamide + Fludarabine | Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) | Recruiting | USA | 0 |
| NCT06047977 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + tumor infiltrating lymphocytes | Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Recruiting | USA | 0 |
| NCT03089203 | Phase I | CART-PSMA-TGF-beta RDN Cyclophosphamide + Fludarabine | CART-PSMA-TGFbetaRDN Cells for Castrate-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT06626256 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + STIL101 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | Not yet recruiting | USA | 0 |
| NCT03326921 | Phase I | Cyclophosphamide + Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |
| NCT06191887 | Phase I | Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Recruiting | USA | 0 |
| NCT05442515 | Phase Ib/II | CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
| NCT07116057 | Phase I | Cyclophosphamide + Fludarabine MOv19-BBz CAR T cells | MOv19-BBz CAR T Cells in FRa+ Cancers | Recruiting | USA | 0 |
| NCT05032820 | Phase II | Cyclophosphamide + Fludarabine Idecabtagene Vicleucel + Lenalidomide | MM CAR-T to Upgrade Response | Completed | USA | 0 |
| NCT04099797 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | Recruiting | USA | 0 |
| NCT03721068 | Phase I | iC9.GD2.CAR.IL-15 T-cells Cyclophosphamide + Fludarabine | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma | Recruiting | USA | 0 |
| NCT05218408 | Phase Ib/II | Cyclophosphamide + Fludarabine CYNK-001 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) | Withdrawn | 0 | |
| NCT06865664 | Phase I | FGFR4 CAR-T cells Cyclophosphamide + Fludarabine | FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma | Recruiting | USA | 0 |
| NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
| NCT05020015 | Phase II | iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active, not recruiting | USA | 0 |
| NCT05972720 | Phase II | Cyclophosphamide + Fludarabine CRG-022 | A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma | Terminated | USA | 0 |
| NCT03338972 | Phase I | Cyclophosphamide + Fludarabine Anti-BCMA CAR-T cells | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
| NCT05672459 | Phase Ib/II | IVS-3001 Cyclophosphamide + Fludarabine | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | Recruiting | USA | 0 |
| NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Completed | USA | 0 |
| NCT07168486 | Phase I | LTG2950 Cyclophosphamide + Fludarabine | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | Enrolling by invitation | USA | 0 |
| NCT03233854 | Phase I | Cyclophosphamide + Fludarabine CD19-22.BB.z CAR T cells NKTR-255 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
| NCT06885697 | Phase I | Cyclophosphamide + Fludarabine TNhYP218 CAR-T cells | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | Recruiting | USA | 0 |
| NCT00003553 | Phase II | Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate | Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer | Completed | USA | 0 |
| NCT06871410 | Phase I | Anti-CD83 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |
| NCT03441100 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin IMA202 | TCR-engineered T Cells in NSCLC and HCC Patients | Completed | USA | DEU | 0 |
| NCT03938987 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) | Recruiting | CAN | 0 |
| NCT05681780 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | Active, not recruiting | USA | 0 |
| NCT03624036 | Phase Ib/II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8) | Terminated | USA | ITA | 0 |
| NCT04639245 | Phase Ib/II | MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | Terminated | USA | 0 |
| NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Active, not recruiting | USA | 0 |
| NCT04526509 | Phase I | Cyclophosphamide + Fludarabine GSK3901961 GSK3845097 | Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | Terminated | USA | SWE | NLD | DEU | CAN | AUS | 0 |
| NCT04551885 | Phase I | Cyclophosphamide + Fludarabine Avelumab + FT516 Aldesleukin | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
| NCT04864054 | Phase II | ECT204 Cyclophosphamide + Fludarabine Regorafenib | T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3) | Recruiting | USA | 1 |
| NCT02932956 | Phase I | Cyclophosphamide + Fludarabine Anti-GPC3-scFvGC33-CAR autologous T lymphocytes | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP) | Active, not recruiting | USA | 0 |
| NCT05092451 | Phase Ib/II | CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | Recruiting | USA | 0 |
| NCT05110742 | Phase Ib/II | CAR.5/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | Active, not recruiting | USA | 0 |
| NCT06364423 | Phase Ib/II | Hu19-CD828Z T cells + Rituximab Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 0 |
| NCT06500273 | Phase II | ALLO-501A Cyclophosphamide + Fludarabine | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) | Recruiting | USA | CAN | 0 |
| NCT05705570 | Phase I | Cyclophosphamide + Fludarabine MB-CART19.1 | Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1) | Recruiting | BRA | 0 |
| NCT02287311 | Phase I | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | Active, not recruiting | USA | 0 |
| NCT04088864 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | Active, not recruiting | USA | 0 |
| NCT06415487 | Phase I | Cyclophosphamide + Fludarabine ACE2016 + Pembrolizumab ACE2016 | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | Recruiting | USA | 1 |
| NCT06045806 | Phase III | Idecabtagene Vicleucel + Lenalidomide Cyclophosphamide + Fludarabine | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) | Active, not recruiting | USA | ROU | POL | NOR | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT | AUS | 2 |
| NCT06151847 | Phase II | Cyclophosphamide + Fludarabine Lifileucel Aldesleukin | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | Recruiting | USA | 0 |
| NCT05400109 | Phase I | Cyclophosphamide + Fludarabine UF-KURE19 | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
| NCT06002659 | Phase Ib/II | Cyclophosphamide + Fludarabine CAR20(NAP) T-cells | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) (CARMA-01) | Recruiting | SWE | 0 |
| NCT07164469 | Phase II | CD70.CAR NK cells + Rimiducid Cyclophosphamide + Fludarabine | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
| NCT04088890 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | Completed | USA | 0 |
| NCT06577025 | Phase II | Ciltacabtagene autoleucel Cyclophosphamide + Fludarabine Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Talquetamab-tgvs Daratumumab + Teclistamab | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (aMMbition) | Active, not recruiting | USA | ESP | DEU | BRA | AUS | 0 |
| NCT03016377 | Phase Ib/II | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | Active, not recruiting | USA | 0 |
| NCT05883449 | Phase II | AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) | Terminated | USA | 0 |
| NCT05707273 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission | Active, not recruiting | USA | 0 |
| NCT06961786 | Phase I | TILT-123 Cyclophosphamide + Fludarabine | TNFa and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma (TUNINTIL-2) | Recruiting | DNK | 0 |
| NCT04678336 | Phase I | CART123 cells Cyclophosphamide + Fludarabine | CD123 Redirected T Cells for AML in Pediatric Subjects | Terminated | USA | 0 |
| NCT06205290 | Phase III | Idelalisib + Rituximab Lisocabtagene maraleucel Cyclophosphamide + Fludarabine Bendamustine + Rituximab | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | Withdrawn | USA | SWE | NOR | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 0 |
| NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Active, not recruiting | USA | AUS | 0 |
| NCT07045909 | Phase II | Cyclophosphamide + Fludarabine Bortezomib + Daratumumab + Dexamethasone + Lenalidomide CART-ddBCMA Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) (GEM-AnitoFIRST) | Recruiting | ESP | 0 |
| NCT03241940 | Phase I | Cyclophosphamide + Fludarabine CD19-22.BB.z CAR T cells | Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
| NCT02153580 | Phase I | Etoposide Cyclophosphamide + Fludarabine Bendamustine | Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia | Active, not recruiting | USA | 0 |
| NCT06879340 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients with Relapsed or Refractory B-cell Malignancies | Recruiting | USA | 0 |
| NCT06609928 | Phase I | Cyclophosphamide + Fludarabine Anti-FOLR1 CAR-T cells | FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
| NCT04377932 | Phase I | Cyclophosphamide + Fludarabine anti-GPC3-IL15-iC9-expressing CAR T-cells | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | Active, not recruiting | USA | 0 |
| NCT06128044 | Phase I | CB-012 Cyclophosphamide + Fludarabine | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMpLify) | Terminated | USA | 0 |
| NCT07222735 | Phase I | Cyclophosphamide + Fludarabine B7-H3 CAR-T cells | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | Recruiting | USA | 0 |
| NCT06413498 | Phase III | Cyclophosphamide + Fludarabine Carfilzomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide CART-ddBCMA Carfilzomib + Dexamethasone | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3) | Recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 1 |
| NCT06043323 | Phase II | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma | Recruiting | USA | 0 |
| NCT06341647 | Phase I | Cyclophosphamide + Fludarabine AB-201 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | Withdrawn | 0 | |
| NCT02869217 | Phase I | Cyclophosphamide + Fludarabine TBI-1301 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | Active, not recruiting | CAN | 0 |
| NCT06241456 | Phase I | Cetuximab + FT825 Bendamustine + Cisplatin + Docetaxel FT825 Cyclophosphamide + Fludarabine | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06480565 | Phase Ib/II | ADI-270 Cyclophosphamide + Fludarabine | A Phase 1/2 Trial of ADI-270 in CcRCC | Active, not recruiting | USA | 0 |
| NCT06358430 | Phase I | Cyclophosphamide + Fludarabine Cetuximab + TROP2-CAR/IL15-transduced CBNK cells | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | Recruiting | USA | 0 |
| NCT05989828 | Phase I | Cyclophosphamide + Fludarabine Autologous anti-HLA-A2/NY-ESO-1 TCR T cells | A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer | Recruiting | USA | 0 |
| NCT04614636 | Phase I | Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538 | FT538 in Subjects With Advanced Hematologic Malignancies | Terminated | USA | 0 |
| NCT06786533 | Phase I | Cyclophosphamide + Fludarabine Anti-FLT3 CAR-T cells | Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/refractory AML | Recruiting | USA | 0 |
| NCT06186401 | Phase I | E-SYNC T cells Cyclophosphamide + Fludarabine | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | Recruiting | USA | 0 |
| NCT06680752 | Phase Ib/II | Cyclophosphamide + Fludarabine ARD103 | Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS | Recruiting | USA | 0 |
| NCT06447987 | Phase I | Cetuximab Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Cyclophosphamide + Fludarabine | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
| NCT03247309 | Phase I | Aldesleukin + IMA201 Cyclophosphamide + Fludarabine | TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) | Completed | USA | DEU | 0 |
| NCT06253520 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Recruiting | USA | 0 |
| NCT06064903 | Phase Ib/II | Cyclophosphamide + Fludarabine CD7-CART01 cells | CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL (CD7-CAR01) | Recruiting | ITA | 0 |
| NCT06342986 | FT536 Cyclophosphamide + Fludarabine | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Recruiting | USA | 0 | |
| NCT06066424 | Phase I | Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Recruiting | USA | 0 |
| NCT06094842 | Phase I | L1CAM-specific CAR+EGFRt+ T cells Bendamustine Cyclophosphamide + Fludarabine | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | Withdrawn | USA | 0 |
| NCT03704298 | Phase Ib/II | axicabtagene ciloleucel + Utomilumab Cyclophosphamide + Fludarabine | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11) | Terminated | USA | 0 |